High pharmacological doses of riboflavin effectively inhibit the HMGB1 release, an important factor in the pathogenesis of endotoxemia [16], and offer a promising therapeutic strategy in sepsis and septic shock as a result of attenuated inflammation, consequently leading to an increase in survival rates among septic animals [32,33,34]. Here, HMGB1 is linked to serum lipopolysaccharide activity.